Syntara Ltd (SNT) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.694x

Based on the latest financial reports, Syntara Ltd (SNT) has a cash flow conversion efficiency ratio of -0.694x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-11.12 Million ≈ $-7.86 Million USD) by net assets (AU$16.02 Million ≈ $11.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Syntara Ltd market capitalisation for the company's overall valuation and market capitalisation.

Syntara Ltd - Cash Flow Conversion Efficiency Trend (2004–2023)

This chart illustrates how Syntara Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Syntara Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Syntara Ltd ranked by their cash flow conversion efficiency. Explore Syntara Ltd cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Tigers Realm Coal Ltd
AU:TIG
-0.316x
Atlantic American Corporation
NASDAQ:AAME
0.061x
Carelabs Co.Ltd
KQ:263700
-0.027x
Audacia SAS
PA:ALAUD
-0.098x
Sangshin Electronics Co. Ltd
KQ:263810
-0.063x
Kyobo 8 Special Purpose Acquisition Company
KQ:307280
0.059x
Spencer's Retail Limited
NSE:SPENCERS
0.084x
VERDE AGRITECH LTD -3918
F:T48
N/A

Annual Cash Flow Conversion Efficiency for Syntara Ltd (2004–2023)

The table below shows the annual cash flow conversion efficiency of Syntara Ltd from 2004 to 2023. View Syntara Ltd (SNT) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2023-06-30 AU$9.56 Million
≈ $6.76 Million
AU$-7.28 Million
≈ $-5.15 Million
-0.761x +49.55%
2022-06-30 AU$10.80 Million
≈ $7.64 Million
AU$-16.30 Million
≈ $-11.54 Million
-1.509x -239.75%
2021-06-30 AU$2.85 Million
≈ $2.01 Million
AU$3.07 Million
≈ $2.17 Million
1.080x +111.63%
2020-06-30 AU$1.43 Million
≈ $1.01 Million
AU$-13.28 Million
≈ $-9.40 Million
-9.283x -594.61%
2019-06-30 AU$14.81 Million
≈ $10.48 Million
AU$-19.80 Million
≈ $-14.01 Million
-1.336x -221.73%
2018-06-30 AU$11.12 Million
≈ $7.87 Million
AU$12.21 Million
≈ $8.64 Million
1.098x +125.33%
2017-06-30 AU$3.52 Million
≈ $2.49 Million
AU$-15.26 Million
≈ $-10.80 Million
-4.335x -656.57%
2016-06-30 AU$20.93 Million
≈ $14.81 Million
AU$-11.99 Million
≈ $-8.48 Million
-0.573x -195.54%
2015-06-30 AU$36.32 Million
≈ $25.70 Million
AU$21.78 Million
≈ $15.41 Million
0.600x +138.51%
2014-06-30 AU$18.07 Million
≈ $12.78 Million
AU$-28.13 Million
≈ $-19.91 Million
-1.557x -198.78%
2013-06-30 AU$67.89 Million
≈ $48.04 Million
AU$-35.38 Million
≈ $-25.04 Million
-0.521x -50.03%
2012-06-30 AU$109.80 Million
≈ $77.69 Million
AU$-38.14 Million
≈ $-26.99 Million
-0.347x +34.15%
2011-06-30 AU$70.83 Million
≈ $50.12 Million
AU$-37.37 Million
≈ $-26.44 Million
-0.528x -52.90%
2010-06-30 AU$115.02 Million
≈ $81.38 Million
AU$-39.68 Million
≈ $-28.08 Million
-0.345x -79.48%
2009-06-30 AU$137.69 Million
≈ $97.43 Million
AU$-26.47 Million
≈ $-18.73 Million
-0.192x -21.48%
2008-06-30 AU$119.12 Million
≈ $84.29 Million
AU$-18.85 Million
≈ $-13.34 Million
-0.158x +41.47%
2007-06-30 AU$76.56 Million
≈ $54.17 Million
AU$-20.70 Million
≈ $-14.64 Million
-0.270x -94.07%
2006-06-30 AU$98.89 Million
≈ $69.97 Million
AU$-13.78 Million
≈ $-9.75 Million
-0.139x +46.58%
2005-06-30 AU$35.57 Million
≈ $25.17 Million
AU$-9.27 Million
≈ $-6.56 Million
-0.261x -50.10%
2004-06-30 AU$26.78 Million
≈ $18.95 Million
AU$-4.65 Million
≈ $-3.29 Million
-0.174x --

About Syntara Ltd

AU:SNT Australia Drug Manufacturers - Specialty & Generic
Market Cap
$27.73 Million
AU$39.19 Million AUD
Market Cap Rank
#24129 Global
#951 in Australia
Share Price
AU$0.02
Change (1 day)
+0.00%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.40
About

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more